Humana's (HUM) New MA Membership Guidance 'Very Positive' - Morgan Stanley

Morgan Stanley analyst Michael Ha reiterated an Overweight rating and $620.00 price target on Humana (NYSE: HUM) after the company rreiterated their 2022/23 EPS guidance. However, more important according to Ha, is the company pdated their 2023 Individual Medicare Advantage (MA) membership growth to "at least" +500k from a prior range of +325-400k on higher than expected sales experienced so far through Annual Enrollment Period (AEP) while additionally anticipating modestly favorable member retention.

This is "very positive" Ha said and confirms their Overweight thesis from their 09/20 upgrade.

"We believe Humana's investments into 2023 has led to an unprecedented improvement in benefit richness we have not historically seen from any traditional MA plan (w/ market share of at least 5%)," the analyst commented. "This has been core to our Humana Upgrade to Overweight thesis since 9/20."

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana are down 0.69% to $546.08 in intra-day trading.

You May Also Be Interested In

• Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
• Humana (HUM) PT Lowered to $360 at Cantor Fitzgerald
• Royal Caribbean Cruises (RCL) PT Raised to $168 at Mizuho